Cargando…

The risk of cardiovascular complications in inflammatory bowel disease

Inflammatory bowel disease (IBD) is a chronic, relapsing disease of unknown etiology involving gastrointestinal tract. IBD comprises two main entities: ulcerative colitis and Crohn’s disease. Several studies showed increased risk of cardiovascular complications in chronic inflammatory disorders, esp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Czubkowski, Piotr, Osiecki, Marcin, Szymańska, Edyta, Kierkuś, Jarosław
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568702/ https://www.ncbi.nlm.nih.gov/pubmed/32785793 http://dx.doi.org/10.1007/s10238-020-00639-y

Ejemplares similares

Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases
por: Fabiszewska, Sylwia, et al.
Publicado: (2021)

Biological markers of disease activity in inflammatory bowel diseases
por: Szymanska, Edyta, et al.
Publicado: (2023)

Sexual functions in individuals with inflammatory bowel diseases
por: Kotkowicz-Szczur, Marta, et al.
Publicado: (2023)

Inflammatory bowel disease – one entity with many molecular faces
por: Szymańska, Sylwia, et al.
Publicado: (2019)

Dual Biologic Therapy in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Retrospective Study
por: Wlazło, Magdalena, et al.
Publicado: (2022)

Premedication Does Not Influence the Incidence of Infliximab Infusion Reactions in Pediatric Patients with Inflammatory Bowel Disease—A Single Center Case–Control Study
por: Szymanska, Edyta, et al.
Publicado: (2021)

Fecal Zonulin as a Noninvasive Biomarker of Intestinal Permeability in Pediatric Patients with Inflammatory Bowel Diseases—Correlation with Disease Activity and Fecal Calprotectin
por: Szymanska, Edyta, et al.
Publicado: (2021)

Demographic characteristics of children with early clinical manifestation of inflammatory bowel disease
por: Szymańska, Edyta, et al.
Publicado: (2015)

The level of faecal calprotectin as a noninvasive biomarker of mucosal healing in children with ulcerative colitis
por: Szymańska, Edyta, et al.
Publicado: (2020)

C-Reactive Protein/Albumin Ratio at Diagnosis of Pediatric Inflammatory Bowel Disease: A Retrospective Multi-Center Study
por: Glapa-Nowak, Aleksandra, et al.
Publicado: (2022)

Insolation and Disease Severity in Paediatric Inflammatory Bowel Disease—A Multi-Centre Cross-Sectional Study
por: Glapa-Nowak, Aleksandra, et al.
Publicado: (2020)

Genetic Variants of DMBT1 and SFTPD and Disease Severity in Paediatric Inflammatory Bowel Disease—A Polish Population-Based Study
por: Glapa-Nowak, Aleksandra, et al.
Publicado: (2021)

Dual Biologic Therapy for the Treatment of Pediatric Inflammatory Bowel Disease: A Review of the Literature
por: Wlazło, Magdalena, et al.
Publicado: (2022)

Apolipoprotein E variants correlate with the clinical presentation of paediatric inflammatory bowel disease: A cross-sectional study
por: Glapa-Nowak, Aleksandra, et al.
Publicado: (2021)

Biosimilar biological drugs in the treatment of inflammatory bowel diseases
por: Kaniewska, Magdalena, et al.
Publicado: (2019)

Profile of infliximab in the treatment of pediatric Crohn’s disease
por: Kierkus, Jaroslaw, et al.
Publicado: (2015)

Biosimilars in paediatric inflammatory bowel disease
por: Sieczkowska-Golub, Joanna, et al.
Publicado: (2018)

Safety profile of biologic therapy in Polish paediatric patients with Crohn's disease
por: Szymanska, Edyta, et al.
Publicado: (2015)

Subjective Psychophysical Experiences in the Course of Inflammatory Bowel Disease—A Comparative Analysis Based on the Polish Pediatric Crohn’s and Colitis Cohort (POCOCO)
por: Glapa-Nowak, Aleksandra, et al.
Publicado: (2021)

Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn’s disease
por: Szymanska, Edyta, et al.
Publicado: (2016)

The impact of induction therapy with three doses of infliximab on deep histological healing in paediatric patients with active Crohn’s disease
por: Szymanska, Edyta, et al.
Publicado: (2016)

Effect of the Crohn’s Disease Exclusion Diet (CDED) on the Fecal Calprotectin Level in Children with Active Crohn’s Disease
por: Matuszczyk, Małgorzata, et al.
Publicado: (2022)

Oral exclusive enteral nutrition for induction of clinical remission, mucosal healing, and improvement of nutritional status and growth velocity in children with active Crohn’s disease – a prospective multicentre trial
por: Matuszczyk, Małgorzata, et al.
Publicado: (2021)

Risk of cardiovascular disease in inflammatory bowel disease
por: Wu, Ping, et al.
Publicado: (2017)

Achalasia in Children—Clinical Presentation, Diagnosis, Long-Term Treatment Outcomes, and Quality of Life
por: Jarzębicka, Dorota, et al.
Publicado: (2021)

Usefulness of Colon Assessment by Magnetic Resonance Enterography in Pediatric Patients with Inflammatory Bowel Disease—Retrospective Case Series
por: Sieczkowska-Golub, Joanna, et al.
Publicado: (2021)

Ocular Complications of Inflammatory Bowel Disease
por: Mady, Rana, et al.
Publicado: (2015)

What Links an Increased Cardiovascular Risk and Inflammatory Bowel Disease? A Narrative Review
por: Łykowska-Szuber, Liliana, et al.
Publicado: (2021)

Supplementation of Bovine Colostrum in Inflammatory Bowel Disease: Benefits and Contraindications
por: Sienkiewicz, Michał, et al.
Publicado: (2020)

Redefining the Practical Utility of Blood Transcriptome Biomarkers in Inflammatory Bowel Diseases
por: Ostrowski, Jerzy, et al.
Publicado: (2019)

Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease
por: Jarmakiewicz-Czaja, Sara, et al.
Publicado: (2022)

Cardiovascular Risk in Individuals with Inflammatory Bowel Disease
por: Biondi, Robertha Baccaro, et al.
Publicado: (2020)

Nutritional Therapy in Pediatric Crohn’s Disease—Are We Going to Change the Guidelines?
por: Matuszczyk, Malgorzata, et al.
Publicado: (2021)

The role of adhesion molecules in inflammatory bowel disease in children. Assessment of the possible risk of cardiovascular complications
por: Trzeciak-Jędrzejczyk, Aneta, et al.
Publicado: (2017)

MicroRNAs in Inflammatory Bowel Disease and Its Complications
por: Krishnachaitanya, Srikruthi S., et al.
Publicado: (2022)

A Review of Ophthalmic Complications in Inflammatory Bowel Diseases
por: Pytrus, Wiktoria, et al.
Publicado: (2022)

Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children
por: Torun, Anna, et al.
Publicado: (2021)

Is Psoriasis Treatment a Risk Factor for Inflammatory Bowel Disease?
por: Nehring, Piotr, et al.
Publicado: (2020)

Cardiovascular implications of inflammatory bowel disease: An updated review
por: Bhardwaj, Arshia, et al.
Publicado: (2023)

Inflammatory bowel disease and pregnancy: fertility, complications and treatment
por: Ali, Mohammad Fahad, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0de7jc096c2u8t8eo7v2k71hb5